Novo Nordisk’s icodec-abae is now approved in the US for type 2 diabetes only, after a prior rejection partly due to concerns about hypoglycemia in type 1 diabetes.
Accelerated approval of semaglutide 7.2 mg establishes a higher-dose, once-weekly GLP-1 RA option for long-term weight reduction under the FDA’s National Priority Voucher framework. STEP UP (n=1407) ...
The FDA has approved Foundayo (orforglipron) as a once‑daily GLP-1 pill to help adults lose excess weight and keep it off ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results